Matthew S. Davids, MD, MMSc

Director, Clinical Research, Division of Lymphoma; Associate Professor of Medicine
Dana-Farber Cancer Institute

Poster(s):

• 1009 - Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL

• 1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL

• 1522 - MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1523 - SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety/Efficacy of AZD0486 as Monotherapy or in Combination With Acalabrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study

• 1912 - A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in chronic lymphocytic leukemia